SCHEMBL21076151

SCHEMBL21076151

Cc1ccc(CCC(C)(C)C)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.52
CYP2A6 P11509 1/20 0.52
TAAR1 Q96RJ0 1/20 0.52
IDO1 P14902 1/20 0.44
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HRH3 Q9Y5N1 1/20 0.42
KCNH2 Q12809 1/20 0.42
HRH1 P35367 1/20 0.41
IGF1R P08069 1/20 0.41
ALOX15 P16050 1/20 0.41
TDP1 Q9NUW8 2/20 0.40
ACHE P22303 1/20 0.40
TSHR P16473 1/20 0.40
AGXT P21549 2/20 0.39
CHKA P35790 1/20 0.39
MEN1 O00255 1/20 0.38
ALDH1A1 P00352 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15164265 0.82 FFAR4 (0.38) CYP1A2CYP2A6TAAR1FFAR1
SCHEMBL9427612 0.81 CYP1A2 (0.54) CYP1A2CYP2A6TAAR1IDO1NPC1
SCHEMBL11471419 0.81 CYP1A2 (0.48) CYP1A2CYP2A6TAAR1IDO1NPC1
SCHEMBL24307776 0.81 CYP1A2 (0.48) CYP1A2CYP2A6TAAR1IDO1NPC1
SCHEMBL12175955 0.81 CYP1A2 (0.48) CYP1A2CYP2A6TAAR1IDO1NPC1
SCHEMBL15803388 0.80 ALDH1A1 (0.47) NPC1SMN1; SMN2TDP1ACHEMEN1
SCHEMBL31277355 0.80 TAAR1 (0.52) CYP2A6TAAR1SMN1; SMN2TDP1TSHR
SCHEMBL8530805 0.79 CYP1A2 (0.46) CYP1A2CYP2A6TAAR1IDO1NPC1
Hydrogen Sulfide SCHEMBL28279959 0.79 CYP1A2 (0.46) CYP1A2CYP2A6TAAR1IDO1NPC1
SCHEMBL21507869 0.78 ESR1 (0.33) KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230021500-A1 CYSTEINE ENGINEERED ANTIBODY-DRUG CONJUGATES WITH PEPTIDE-CONTAINING LINKERS MERSANA THERAPEUTICS, INC. 2023-01-26 US disclosed
US-20190167685-A1 SELECTIVE CALCIUM CHANNEL ANTAGONISTS NORTHWESTERN UNIVERSITY 2019-06-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190167685-A1 SELECTIVE CALCIUM CHANNEL ANTAGONISTS CACNA1C, CACNA1B, CACNA1G CYP1A2 4681/4885CYP2A6 4675/4885TAAR1 1963/4885
US-20230021500-A1 CYSTEINE ENGINEERED ANTIBODY-DRUG CONJUGATES WITH PEPTIDE-CONTAINING LINKERS LNPEP, DNPEP, QPCT CYP1A2 4735/4885CYP2A6 3851/4885TAAR1 3740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.